Skip to content
TheChatArchiveThe Chat Archive
gpt-4o-2024-08-06· OpenAIAi2 WildChat-4.8M (AI2)

You act as a paraphrase tool. Your role involves understanding the provided text…

  1. User

    System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words, and then provide a negative example that keeps the words similar while changing the meaning of the original text. Output your response with the following format : Positive example: Negative example:

    User: We do not currently own or operate a manufacturing facility. Previously, we utilized Pharmaceutical Manufacturing Research Services, Inc. as our CDMO for the manufacture of our products used in pre-clinical research and clinical trials. In October 2022, we retained Societal as our new CDMO that will manufacture all clinical, registration, and commercial batches of our lead candidate CTx-1301. Societal will dedicate a specific manufacturing suite within its Gainesville, GA facility and outfit it with proprietary equipment owned by us. Any third-party manufacturers, facilities, and all lots of drug substance and drug products used in our clinical trials are required to be in compliance with cGMPs. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports, and returned or salvaged products. The manufacturing facilities where our products are produced must meet cGMP requirements and FDA satisfaction before any product is approved and we can manufacture commercial products. Any third-party manufacturers are also subject to periodic inspections of facilities by the FDA and other authorities, including procedures and operations used in the testing and manufacture of our products to assess our compliance with applicable regulations. In addition, our drug products are classified as Class II controlled substances which requires any future third-party manufacturers to be approved and regulated by the United States Federal Drug Enforcement Agency (the “DEA”). Assistant:

  2. Assistant

    Positive example: We do not have a manufacturing facility at present. In the past, we worked with Pharmaceutical Manufacturing Research Services, Inc. as our contract development and manufacturing organization (CDMO) for producing our products for pre-clinical studies and clinical trials. In October 2022, we appointed Societal as our new CDMO to manufacture all clinical, registration, and commercial batches of our leading product candidate, CTx-1301. Societal will assign a designated manufacturing area within its Gainesville, GA plant and equip it with our proprietary machinery. Any third-party producers, facilities, and all batches of drug substances and drug products in our clinical trials are obligated to adhere to current Good Manufacturing Practices (cGMPs). The cGMP guidelines include prerequisites concerning personnel organization, building and facility standards, equipment, management of components as well as packaging materials, production and process oversight, packaging and labeling regulations, storage and shipping, laboratory checks, documentation, and handling of returned or salvaged goods. The production sites for our products must satisfy cGMP standards and gain FDA approval before commercial manufacturing can proceed. Third-party manufacturers are also liable to routine inspections by the FDA and other regulatory bodies to ensure compliance with pertinent laws and operational standards in the testing and production of our items. Additionally, since our drug products are deemed Class II controlled substances, any upcoming third-party manufacturers need approval and supervision by the U.S. Federal Drug Enforcement Agency (the “DEA”).

    Negative example: We have several manufacturing facilities that we own and operate. In the future, we plan to utilize a different company instead of Pharmaceutical Manufacturing Research Services, Inc. as our CDMO for the manufacture of products used in our clinical trials. We have not yet decided on appointing Societal as our new CDMO in October 2022 to produce clinical, registration, and commercial batches of CTx-1301. FDA approval is not necessary for our current manufacturing processes, and our drug products are not subject to DEA regulations.